肾下腹主动脉腔内修复术后移植物感染的单中心二十年经验
单中心回顾性分析2000年至2022年1274例标准EVAR患者,29例移植物感染,累积感染率1.7%,发病率为每1000患者年2.69例。共32例接受治疗,其中22例移植物切除并原位生物材料重建,30天死亡率为19.0%,90天为23.8%。生物重建组3年生存率68.2%,保守治疗组22.2%(P=0.002)。
要点
- EVAR移植物感染累积发生率1.7%,中位感染时间8.4个月。
- 感染后移植物切除并原位生物重建30天死亡率19.0%,90天23.8%。
- 生物重建组3年生存率68.2%,保守治疗组22.2%(P=0.002)。
核心结论
- EVAR移植物切除并原位生物主动脉重建为EVAR感染提供了一种可行、抗感染且持久的解决方案。
研究设计与样本
- 单中心回顾性研究,从2000年1月至2022年12月的前瞻性血管外科数据库中提取所有标准EVAR患者,通过病历回顾识别EVAR后感染。
- 共1274例患者中29例EVAR移植物感染,加上其他机构3例,共32例患者接受治疗。
主要发现
- 平均总随访6.36年(范围4.4个月至23.3年),累积感染率1.7%,择期EVAR患者组发病率为每1000患者年2.69例。
- 感染中位时间8.4个月(范围9天至11.4年)。
- 32例中女性仅2例(6.3%),9例(28.1%)保守治疗,1例采用移植物保留策略,22例(69%)行移植物切除并原位重建。
- 22例重建中,19例(86.4%)使用自体股静脉,2例(9.1%)使用冷冻保存同种异体股静脉,1例(4.5%)使用利福平浸泡的涤纶人工血管。
- 移植物切除并原位重建患者早期术后死亡率30天为19.0%(21例中4例),90天为23.8%(21例中5例)。
临床怎么用
- 本研究中心20年来的主要治疗方法是切除感染移植物并原位使用生物材料重建。
- 作者认为EVAR移植物切除并原位生物主动脉重建是治疗EVAR感染的可行、抗感染且持久的解决方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To study the incidence of endovascular aneurysm repair (EVAR) graft infections and to examine the results of treatment at a single institution, where the mainstay of treatment has for 20 years been to explant the infected grafts and to reconstruct in situ with biological materials. METHODS: All standard EVAR patients treated from January 2000 to December 2022 at our institution were extracted from a prospective vascular surgery database, and post-EVAR infections were identified through a chart review and analyzed retrospectively. Primary endpoints were short-term (30-day and 90-day) mortality and mid-term survival. Secondary endpoints were freedom from reinfections and freedom from reinterventions. RESULTS: A total of 29 EVAR grafts in 1,274 patients became infected during a mean total follow-up of 6.36 years (range 4.4 months-23.3 years). The cumulative rate of infections was 1.7%, and the incidence rate was 2.69 cases per 1,000 patient-years in the patient group where the primary EVAR was performed in an elective setting. The median time to infection was 8.4 months (range: 9 days-11.4 years). With 3 additional patients from other institutions, a total of 32 patients underwent treatment for an EVAR graft infection. Only 2 patients (6.3%) were female. Nine patients (28.1%) were treated conservatively, 1 patient was operated with a graft preservation strategy and the rest (n = 22, 69%) underwent graft explantation and in situ reconstruction. In these 22 reconstructions, the graft material used was an autologous femoral vein in 19 (86.4%) patients, a cryopreserved allogenous femoral vein in 2 (9.1%) patients, and a rifampicin-soaked dacron prosthesis in 1 (4.5%) patient. The early postoperative mortality was 19.0% (n = 4 of 21) at 30 days and 23.8% (n = 5 of 21) at 90 days for the patients with explanted grafts with in-situ reconstruction, while survival at 1 year was 76.2% (n = 16 of 21) for the group treated with biological reconstruction and 44.4% (n = 4 of 9) for the conservatively treated patients. Similarly, in Kaplan-Meier analysis, the 3-year survival was 68.2% and 22.2%, respectively (P = 0.002). During a median follow-up of 2.3 years (range: 3 days-12.4 years), there were no reinfections among patients with biological reconstructions, and none of the patients required late graft reinterventions. CONCLUSION: EVAR graft explantation and in situ biological aortic reconstruction offers a viable, infection-resistant and durable solution for the treatment of EVAR infection.
引用
- Järvinen I, Heinola I, Kantonen I, et al. Two-Decade Single-Center Experience with Graft Infections After Infrarenal Endovascular Aortic Repair. Ann Vasc Surg. 2025. PMID: 40368323. doi:10.1016/j.avsg.2025.04.132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。